1 Department of Respiratory and Sleep Medicine, Hunter Medical Research Institute, John Hunter Hospital, Newcastle, NSW 2310, and Cooperative Research Centre for Asthma, Camperdown, NSW 2050, ...
Antileukotriene drugs are new therapeutic agents that have recently been approved for the treatment of asthma. Several cases of eosinophilic conditions including Churg-Strauss syndrome have been ...
Background: Chronic cough that persists despite medical treatment may respond to speech pathology intervention, but the efficacy of such treatment has not been investigated in prospective randomised ...
Background: Interstitial lung disease (ILD) is characterised by exertional dyspnoea, exercise limitation and reduced quality of life. The role of exercise training in this diverse patient group is ...
The number of asthma deaths among children and young people (CYP) in the UK has remained stubbornly constant despite advances in medication, delivery systems and maintenance and reliever therapy ...
Introduction and objectives The last comprehensive survey of UK respiratory disease epidemiology was the British Thoracic Society’s 2006 Burden of Lung Disease report. We performed an analysis ...
Background The diagnosis and management of pneumonia is often challenging due to its overlapping clinical presentations with other respiratory illnesses, low pathogen identification rates, and slow ...
2 University Department of Child Health, Sheffield Children’s Hospital, Sheffield, UK 3 Department of Respiratory and Neonatal Paediatrics, Liverpool Women’s Hospital, Liverpool, UK During a recent ...
2 Department of Pulmonary and Cardiac Rehabilitation, Coventry University, School of Health and Life Sciences, Coventry, UK 3 Clinical Trials Unit, Warwick Medical School, The University of Warwick, ...
Background There is accumulating evidence for an overly activated immune response in severe COVID-19, with several studies exploring the therapeutic role of immunomodulation. Through systematic review ...
Background Risk factors for COPD in high-income settings are well understood; however, less attention has been paid to contributors of COPD in low-income and middle-income countries (LMICs) such as ...
Academic Respiratory Medicine, St Bartholomew's and Royal London Schools of Medicine and Dentistry and London Chest Hospital, London, UK Dr J A Wedzicha, Academic Respiratory Medicine, Dominion House, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback